Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab177850-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab177850-1mg | 1mg | In stock | $279.90 | |
| Ab177850-5mg | 5mg | In stock | $909.90 | |
| Ab177850-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,429.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Galiximab (anti-CD80) - Primary antibody, specific to CD80, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Activation B7-1 antigen antibody; B lymphocyte activation antigen B7 antibody; B7 antibody; B7-1 antibody; B7-1 antigen antibody; B7.1 antibody; BB1 antibody; CD28 antigen ligand 1 antibody; CD28LG antibody; CD28LG1 antibody; CD80 antibody; CD80 antigen ( |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD80 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of T-lymphocyte activation antigen CD80 inhibitor |
| Product Description | Galiximab (anti-CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab (anti-CD80) has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab (anti-CD80) can be used in research of B-cell lymphoma. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | lambda |
| SDS-PAGE | 28.8 kDa (Light Chain) & 51.6 kDa (Heavy Chain), under reducing conditions; 183.4 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 357613-77-5 |
Galiximab (anti-CD80) (Ab177850) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD80 (red) with Galiximab (anti-CD80) (Ab177850). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Galiximab (anti-CD80) (Ab177850) - SEC
The purity of Galiximab (anti-CD80) (Ab177850) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1202072 | Certificate of Analysis | Dec 20, 2023 | Ab177850 |
| ZJ23F1202073 | Certificate of Analysis | Dec 20, 2023 | Ab177850 |
| 1. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. (2013) Update on the use of abatacept for the treatment of rheumatoid arthritis.. Expert Rev Clin Immunol, 9 (7): (599-621). [PMID:23899231] |
| 2. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933] |
| 3. Selvakumar, A A and 5 more authors.. (1992) Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7.. Immunogenetics, [PMID:1377173] |
| 4. Freeman, G J GJ and 8 more authors.. (1991) Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.. The Journal of experimental medicine, (1): [PMID:1714935] |
| 5. Freeman, G J GJ and 5 more authors.. (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:2794510] |
| 6. Lanier, L L LL and 7 more authors.. (1995) CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:7527824] |
| 7. Vandenborre, K K and 5 more authors.. (1999) Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.. Immunology, [PMID:10583602] |
| 8. Ikemizu, S S and 7 more authors.. (2000) Structure and dimerization of a soluble form of B7-1.. Immunity, [PMID:10661405] |
| 9. Stamper, C C CC and 9 more authors.. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.. Nature, (29): [PMID:11279502] |
| 10. Gottlieb, Alice B AB and 8 more authors.. (2004) Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.. Clinical immunology (Orlando, Fla.), [PMID:15093549] |
| 11. Czuczman, Myron S MS and 13 more authors.. (2005) Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1): [PMID:15994148] |
| 12. and Kremer, Joel M JM.. (2005) Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis.. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, [PMID:16357751] |
| 13. Hervey, Pauline S PS and Keam, Susan J SJ.. (2006) Abatacept.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:16573350] |
| 14. Muzny, Donna M DM and 113 more authors.. (2006) The DNA sequence, annotation and analysis of human chromosome 3.. Nature, (27): [PMID:16641997] |
| 15. Weyand, Cornelia M CM and Goronzy, Jörg J JJ.. (2006) T-cell-targeted therapies in rheumatoid arthritis.. Nature clinical practice. Rheumatology, [PMID:16932686] |
| 16. and Scheinfeld, Noah N.. (2006) Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.. The Journal of dermatological treatment, [PMID:16971318] |
| 17. Tedesco Silva, Helio H, Pinheiro Machado, Paula P, Rosso Felipe, Claudia C and Medina Pestana, Jose Osmar JO.. (2006) Immunotherapy for De Novo renal transplantation: what's in the pipeline?. Drugs, [PMID:16978033] |
| 18. Vincenti, Flavio F and Luggen, Michael M.. (2007) T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.. Annual review of medicine, [PMID:17020493] |
| 19. Nogid, Anna A and Pham, David Q DQ.. (2006) Role of abatacept in the management of rheumatoid arthritis.. Clinical therapeutics, [PMID:17212998] |
| 20. Leonard, J P JP and 14 more authors.. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.. Annals of oncology : official journal of the European Society for Medical Oncology, [PMID:17470451] |
| 21. Kakoulidou, M M, Giscombe, R R, Zhao, X X, Lefvert, A K AK and Wang, X X.. (2007) Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.. Scandinavian journal of immunology, [PMID:17953528] |
| 22. Reynolds, Jennifer J, Shojania, Kam K and Marra, Carlo A CA.. (2007) Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.. Pharmacotherapy, [PMID:18041889] |
| 23. Maxwell, Lara J LJ and Singh, Jasvinder A JA.. (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review.. The Journal of rheumatology, [PMID:20080922] |
| 24. Kleinpeter, Patricia and 20 more authors.. (2019) By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.. Journal of virology, (1): [PMID:30918073] |
